F. Johnson

发表

Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers

P. Mudd, F. Johnson, Salim Janmohamed, 2015, Clinical pharmacology in drug development.

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders

K. Romero, V. Sinha, F. Johnson, 2019, Orphanet Journal of Rare Diseases.

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users

L. Webster, F. Johnson, Joseph W. Stauffer, 2011, Drugs in R&D.

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

D. Lockhart, J. Flanagan, C. Barlow, 2015, PloS one.

Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice

R. Schiffmann, F. Johnson, A. Das, 2021, Clinical pharmacology in drug development.

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α

D. Lockhart, B. Byrne, J. Flanagan, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.

F. Johnson, B. Setnik, 2011, Pain physician.

Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine

G. Kearns, A. Staiano, C. Dupont, 2004, Journal of pediatric gastroenterology and nutrition.

The Bioequivalence of Nizatidine (Axid®) in Two Extemporaneously and One Commercially Prepared Oral Liquid Formulations Compared with Capsule

G. Kearns, S. Abdel‐Rahman, F. Johnson, 2003, Journal of clinical pharmacology.

Single‐Dose Pharmacokinetics of Nizatidine (Axid®) in Children

G. Kearns, S. Abdel‐Rahman, F. Johnson, 2002, Journal of clinical pharmacology.

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

D. Lockhart, R. Schiffmann, C. Barlow, 2016, Journal of Medical Genetics.

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

D. Lockhart, S. Packman, R. Schiffmann, 2016, The New England journal of medicine.

Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers

P. Mudd, F. Johnson, A. Bragat, 2013, Clinical pharmacology in drug development.

Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules.

F. Johnson, Joseph W. Stauffer, G. Wagner, 2008, The journal of pain : official journal of the American Pain Society.

Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.

F. Johnson, J. Stark, Joseph W. Stauffer, 2010, Clinical Therapeutics.

(260) Efficacy and safety evaluation of an extended-release morphine sulfate formulation with sequestered naltrexone for the treatment of osteoarthritis

F. Johnson, Nathaniel Katz, Joseph W. Stauffer, 2008 .

ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.

F. Johnson, Nathaniel Katz, Joseph W. Stauffer, 2010, The journal of pain : official journal of the American Pain Society.

The Relative Bioavailability of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules (EMBEDA®) and an Extended Release Morphine Sulfate Capsule Formulation (KADIAN®) in Healthy Adults Under Fasting Conditions

F. Johnson, Joseph W. Stauffer, J. Kisicki, 2011, American journal of therapeutics.

Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.

R. Brewer, L. Webster, F. Johnson, 2010, Journal of pain and symptom management.

Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules

F. Johnson, Joseph W. Stauffer, S. Boudriau, 2010, Advances in therapy.

Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users

E. Sellers, F. Johnson, Joseph W. Stauffer, 2009, Clinical drug investigation.

Effects of Alcohol on the Pharmacokinetics of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules

F. Johnson, Joseph W. Stauffer, J. Kisicki, 2012, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of a Novel Nizatidine Controlled‐Release Formulation in Healthy Subjects

F. Johnson, R. Blum, A. Braverman, 2003, Journal of clinical pharmacology.

An open‐label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function

C. Barlow, P. Mudd, F. Johnson, 2015, Clinical pharmacology in drug development.

Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate‐release morphine with ethanol in healthy male participants

F. Johnson, B. Setnik, M. Romach, 2014, Human psychopharmacology.

ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.

F. Johnson, Nathaniel Katz, Joseph W. Stauffer, 2010, The journal of pain : official journal of the American Pain Society.